CDP791 is a PEGylated di-Fab′ antibody that binds with high affinity to VEGFR2 and blocks VEGF binding. In a Phase I clinical trial of CDP791, several patients developed cutaneous hemangiomata arising 28 to 106 days after the first drug administration and resolving after cessation. The cover shows immunohistochemical analysis of a hemangioma biopsy indicating that VEGFR2 is nonphosphorylated. Additional immunohistochemistry shows the presence of CDP791 and suggests inhibition of VEGFR2 signaling in these lesions. For further details, please see the article by Ton and associates on page 7113 of this issue.

[Table of Contents]